Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 256 to 270 of 303 results for breast cancer

  1. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued [GID-TA10264]

    Technology appraisal guidance
    Discontinued

  2. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued [GID-TA10570]

    Technology appraisal guidance
    Discontinued

  3. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued [GID-TA10028]

    Technology appraisal guidance
    Discontinued

  4. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued [GID-TAG403]

    Technology appraisal guidance
    Discontinued

  5. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued [GID-TA10539]

    Technology appraisal guidance
    Discontinued

  6. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

    Technology appraisal guidance
    Discontinued

  7. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued [GID-TA10591]

    Technology appraisal guidance
    Discontinued

  8. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued [GID-TA11178]

    Technology appraisal guidance
    Discontinued

  9. Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]

    Discontinued [GID-TAG410]

    Technology appraisal guidance
    Discontinued

  10. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued [GID-TA10309]

    Technology appraisal guidance
    Discontinued

  11. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781

    Awaiting development [GID-TA11110] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]

    Awaiting development [GID-TA10960] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    Awaiting development [GID-TA11089] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Awaiting development [GID-TA11339] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development [GID-TA10261] Expected publication date: TBC

    Technology appraisal guidance
    In development